Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05135000 · ClinicalTrials.gov registry record · Phase 2
Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT05135000 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 47 participants.
The verdict
NCT05135000, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
The purpose of this study was to explore the efficacy and safety of LTP001 in participants with pulmonary arterial hypertension (PAH) to determine if LTP001 had an adequate clinical profile to warrant further clinical development in this indication.
Interventions
- DRUG Placebo
- DRUG LTP001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2022-06-30 |
| Est. Completion | 2024-04-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05135000
The ClinicalTrials.gov registry entry for NCT05135000 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05135000 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05135000 about?
NCT05135000 is a clinical study titled "Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension". The purpose of this study was to explore the efficacy and safety of LTP001 in participants with pulmonary arterial hypertension (PAH) to determine if LTP001 had an adequate clinical profile to warrant further clinical development in this indication.
What is the current status of trial NCT05135000?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2022-06-30. Estimated completion is 2024-04-25.
What interventions are being tested in trial NCT05135000?
The interventions under investigation include: Placebo (DRUG), LTP001 (DRUG).
Who is sponsoring clinical trial NCT05135000?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.